JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Journal of Nuclear Medicine Vol. 40 No. 11 1771-1777
© 1999 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weber, W. A.
Right arrow Articles by Schwaiger, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weber, W. A.
Right arrow Articles by Schwaiger, M.

Reproducibility of Metabolic Measurements in Malignant Tumors Using FDG PET

Wolfgang A. Weber, Sibylle I. Ziegler, Ralf Thödtmann, Axel-R. Hanauske and Markus Schwaiger

Nuklearmedizinische Klinik and I. Medizinische Klinik, Klinikum Rechts der Isar, Technische Universität München, München, Germany

Correspondence: For correspondence or reprints contact: Wolfgang A. Weber, MD, Nuklearmedizinische Klinik, Klinikum Rechts der Isar, Ismaningerstr. 22, 81675 München, Germany.

ABSTRACT

PET using 18F-fluorodeoxyglucose (FDG) is increasingly applied to monitor the response of malignant tumors to radiotherapy and chemotherapy. The aim of this study was to assess the reproducibility of serial FDG PET measurements to define objective criteria for the evaluation of treatment-induced changes. Methods: Sixteen patients participating in phase I studies of novel antineoplastic compounds were examined twice by FDG PET within 10 d while they were receiving no therapy. Standardized uptake values (SUVs), FDG net influx constants (Kj), glucose normalized SUVs (SUVgluc) and influx constants (Kj,gluc) w ere determined for 50 separate lesions. The precision of repeated measurements was determined on a lesion-by-lesion and a patient-by-patient basis. Results: None of the parameters showed a significant increase or decrease at the two examinations. The differences of repeated measurements were approximately nor mally distributed for all parameters with an SD of the mean percentage difference of about 10%. The 95% normal ranges for spontaneous fluctuations of SUV, SUVgluc, Kj and Kj,gluc were determined to be ±0.91, ±1.14, ±0.52 mL/100 g/min and ±0.64 mL/100 g/min, respectively. Analysis on a lesion-by-lesion basis yielded similar results. Conclusion: FDG PET provides several highly reproducible quantitative parameters of tumor glucose metabolism. Changes of a parameter that are outside the 95% normal range determined in this study may be used to define a metabolic response to therapy.

Key Words: PET • fluorodeoxyglucose • therapy monitoring




This article has been cited by other articles:


Home page
 JNMHome page
K. Herrmann, F. Eckel, S. Schmidt, K. Scheidhauer, B. J. Krause, J. Kleeff, T. Schuster, H.-J. Wester, H. Friess, R. M. Schmid, et al.
In Vivo Characterization of Proliferation for Discriminating Cancer from Pancreatic Pseudotumors
J. Nucl. Med., September 1, 2008; 49(9): 1437 - 1444.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. F. Shields, J. M. Lawhorn-Crews, D. A. Briston, S. Zalzala, S. Gadgeel, K. A. Douglas, T. J. Mangner, L. K. Heilbrun, and O. Muzik
Analysis and Reproducibility of 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Imaging in Patients with Non-Small Cell Lung Cancer
Clin. Cancer Res., July 15, 2008; 14(14): 4463 - 4468.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. R. Benz, V. Evilevitch, M. S. Allen-Auerbach, F. C. Eilber, M. E. Phelps, J. Czernin, and W. A. Weber
Treatment Monitoring by 18F-FDG PET/CT in Patients with Sarcomas: Interobserver Variability of Quantitative Parameters in Treatment-Induced Changes in Histopathologically Responding and Nonresponding Tumors
J. Nucl. Med., July 1, 2008; 49(7): 1038 - 1046.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
C. Calcagno, J.-C. Cornily, F. Hyafil, J. H.F. Rudd, K. C. Briley-Saebo, V. Mani, G. Goldschlager, J. Machac, V. Fuster, and Z. A. Fayad
Detection of Neovessels in Atherosclerotic Plaques of Rabbits Using Dynamic Contrast Enhanced MRI and 18F-FDG PET
Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1311 - 1317.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. J. de Langen, V. E. M. van den Boogaart, J. T. Marcus, and M. Lubberink
Use of H215O-PET and DCE-MRI to Measure Tumor Blood Flow
Oncologist, June 1, 2008; 13(6): 631 - 644.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. L. Frost, G. M. Blake, S.-J. Park-Holohan, G. J.R. Cook, K. M. Curran, P. K. Marsden, and I. Fogelman
Long-Term Precision of 18F-Fluoride PET Skeletal Kinetic Studies in the Assessment of Bone Metabolism
J. Nucl. Med., May 1, 2008; 49(5): 700 - 707.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. S. Boss, R. V. Olmos, M. Sinaasappel, J. H. Beijnen, and J. H. M. Schellens
Application of PET/CT in the Development of Novel Anticancer Drugs
Oncologist, January 1, 2008; 13(1): 25 - 38.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
K. Herrmann, K. Ott, A. K. Buck, F. Lordick, D. Wilhelm, M. Souvatzoglou, K. Becker, T. Schuster, H.-J. Wester, J. R. Siewert, et al.
Imaging Gastric Cancer with PET and the Radiotracers 18F-FLT and 18F-FDG: A Comparative Analysis
J. Nucl. Med., December 1, 2007; 48(12): 1945 - 1950.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. J. Beer, A.-L. Grosu, J. Carlsen, A. Kolk, M. Sarbia, I. Stangier, P. Watzlowik, H.-J. Wester, R. Haubner, and M. Schwaiger
[18F]Galacto-RGD Positron Emission Tomography for Imaging of {alpha}v{beta}3 Expression on the Neovasculature in Patients with Squamous Cell Carcinoma of the Head and Neck
Clin. Cancer Res., November 15, 2007; 13(22): 6610 - 6616.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. Hellwig, T. P. Graeter, D. Ukena, A. Groeschel, G. W. Sybrecht, H.-J. Schaefers, and C.-M. Kirsch
18F-FDG PET for Mediastinal Staging of Lung Cancer: Which SUV Threshold Makes Sense?
J. Nucl. Med., November 1, 2007; 48(11): 1761 - 1766.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Chen, S. Delaloye, D. H.S. Silverman, C. Geist, J. Czernin, J. Sayre, N. Satyamurthy, W. Pope, A. Lai, M. E. Phelps, et al.
Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [18F] Fluorothymidine Positron Emission Tomography: A Pilot Study
J. Clin. Oncol., October 20, 2007; 25(30): 4714 - 4721.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. J. Cerfolio and A. S. Bryant
When is it Best to Repeat a 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Scan on Patients with Non-Small Cell Lung Cancer Who Have Received Neoadjuvant Chemoradiotherapy?
Ann. Thorac. Surg., October 1, 2007; 84(4): 1092 - 1097.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. H.F. Rudd, K. S. Myers, S. Bansilal, J. Machac, A. Rafique, M. Farkouh, V. Fuster, and Z. A. Fayad
18Fluorodeoxyglucose Positron Emission Tomography Imaging of Atherosclerotic Plaque Inflammation Is Highly Reproducible: Implications for Atherosclerosis Therapy Trials
J. Am. Coll. Cardiol., August 28, 2007; 50(9): 892 - 896.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
K. Frank-Raue, M. Fabel, S. Delorme, U. Haberkorn, and F. Raue
Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma
Eur. J. Endocrinol., August 1, 2007; 157(2): 215 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Herrmann, H. A. Wieder, A. K. Buck, M. Schoffel, B.-J. Krause, F. Fend, T. Schuster, C. Meyer zum Buschenfelde, H.-J. Wester, J. Duyster, et al.
Early Response Assessment Using 3'-Deoxy-3'-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma
Clin. Cancer Res., June 15, 2007; 13(12): 3552 - 3558.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Soret, S. L. Bacharach, and I. Buvat
Partial-Volume Effect in PET Tumor Imaging
J. Nucl. Med., June 1, 2007; 48(6): 932 - 945.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. K. Doot, L. K. Dunnwald, E. K. Schubert, M. Muzi, L. M. Peterson, P. E. Kinahan, B. F. Kurland, and D. A. Mankoff
Dynamic and Static Approaches to Quantifying 18F-FDG Uptake for Measuring Cancer Response to Therapy, Including the Effect of Granulocyte CSF
J. Nucl. Med., June 1, 2007; 48(6): 920 - 925.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
G. S.P. Meirelles, Y. E. Erdi, S. A. Nehmeh, O. D. Squire, S. M. Larson, J. L. Humm, and H. Schoder
Deep-Inspiration Breath-Hold PET/CT: Clinical Findings with a New Technique for Detection and Characterization of Thoracic Lesions
J. Nucl. Med., May 1, 2007; 48(5): 712 - 719.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Dandekar, J. R. Tseng, and S. S. Gambhir
Reproducibility of 18F-FDG microPET Studies in Mouse Tumor Xenografts
J. Nucl. Med., April 1, 2007; 48(4): 602 - 607.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Kawada, K. Murakami, T. Sato, Y. Kojima, H. Ebi, H. Mukai, M. Tahara, K. Shimokata, and H. Minami
Prospective Study of Positron Emission Tomography for Evaluation of the Activity of Lapatinib, a Dual Inhibitor of the ErbB1 and ErbB2 Tyrosine Kinases, in Patients with Advanced Tumors
Jpn. J. Clin. Oncol., January 1, 2007; 37(1): 44 - 48.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. A. Weber and R. Figlin
Monitoring Cancer Treatment with PET/CT: Does It Make a Difference?
J. Nucl. Med., January 1, 2007; 48(1_suppl): 36S - 44S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. M. Linden, K. A. Krohn, R. B. Livingston, and D. A. Mankoff
Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
Clin. Cancer Res., October 1, 2006; 12(19): 5608 - 5610.
[Full Text] [PDF]

Home page
 JNMHome page
Y. S. Jhanwar and D. J. Straus
The Role of PET in Lymphoma
J. Nucl. Med., August 1, 2006; 47(8): 1326 - 1334.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K.-H. Lee, S.-H. Lee, D.-W. Kim, W. J. Kang, J.-K. Chung, S.-A. Im, T.-Y. Kim, Y. W. Kim, Y.-J. Bang, and D. S. Heo
High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy.
Clin. Cancer Res., July 15, 2006; 12(14): 4232 - 4236.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. A. Weber
Positron Emission Tomography As an Imaging Biomarker
J. Clin. Oncol., July 10, 2006; 24(20): 3282 - 3292.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. J. Beer, R. Haubner, M. Sarbia, M. Goebel, S. Luderschmidt, A. L. Grosu, O. Schnell, M. Niemeyer, H. Kessler, H.-J. Wester, et al.
Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin {alpha}v{beta}3 Expression in Man.
Clin. Cancer Res., July 1, 2006; 12(13): 3942 - 3949.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. K. Shankar, J. M. Hoffman, S. Bacharach, M. M. Graham, J. Karp, A. A. Lammertsma, S. Larson, D. A. Mankoff, B. A. Siegel, A. Van den Abbeele, et al.
Consensus Recommendations for the Use of 18F-FDG PET as an Indicator of Therapeutic Response in Patients in National Cancer Institute Trials
J. Nucl. Med., June 1, 2006; 47(6): 1059 - 1066.
[Full Text] [PDF]

Home page
 JCOHome page
C. J. Hoekstra, S. G. Stroobants, E. F. Smit, J. Vansteenkiste, H. van Tinteren, P. E. Postmus, R. P. Golding, B. Biesma, F. J.H.M. Schramel, N. van Zandwijk, et al.
Prognostic Relevance of Response Evaluation Using [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., November 20, 2005; 23(33): 8362 - 8370.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. R. Tseng, M. Dandekar, M. Subbarayan, Z. Cheng, J. M. Park, S. Louie, and S. S. Gambhir
Reproducibility of 3'-Deoxy-3'-18F-Fluorothymidine MicroPET Studies in Tumor Xenografts in Mice
J. Nucl. Med., November 1, 2005; 46(11): 1851 - 1857.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
W A Weber
PET for response assessment in oncology: radiotherapy and chemotherapy
Br. J. Radiol., November 1, 2005; Supplement_28(1): 42 - 49.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Avril, S. Sassen, B. Schmalfeldt, J. Naehrig, S. Rutke, W. A. Weber, M. Werner, H. Graeff, M. Schwaiger, and W. Kuhn
Prediction of Response to Neoadjuvant Chemotherapy by Sequential F-18-Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced-Stage Ovarian Cancer
J. Clin. Oncol., October 20, 2005; 23(30): 7445 - 7453.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
M. Westerterp, H. L. van Westreenen, J. B. Reitsma, O. S. Hoekstra, J. Stoker, P. Fockens, P. L. Jager, B. L. F. Van Eck-Smit, J. T. M. Plukker, J. J. B. van Lanschot, et al.
Esophageal Cancer: CT, Endoscopic US, and FDG PET for Assessment of Response to Neoadjuvant Therapy--Systematic Review
Radiology, September 1, 2005; 236(3): 841 - 851.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. Dose Schwarz, M. Bader, L. Jenicke, G. Hemminger, F. Janicke, and N. Avril
Early Prediction of Response to Chemotherapy in Metastatic Breast Cancer Using Sequential 18F-FDG PET
J. Nucl. Med., July 1, 2005; 46(7): 1144 - 1150.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Wells, R. N. Gunn, C. Steel, A. S. Ranicar, F. Brady, S. Osman, T. Jones, and P. Price
2-[11C]Thymidine Positron Emission Tomography Reproducibility in Humans
Clin. Cancer Res., June 15, 2005; 11(12): 4341 - 4347.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. A. Weber
Use of PET for Monitoring Cancer Therapy and for Predicting Outcome
J. Nucl. Med., June 1, 2005; 46(6): 983 - 995.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al.
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
Y.-Y. Yau, W.-S. Chan, Y.-M. Tam, P. Vernon, S. Wong, M. Coel, and S. K.-F. Chu
Application of Intravenous Contrast in PET/CT: Does It Really Introduce Significant Attenuation Correction Error?
J. Nucl. Med., February 1, 2005; 46(2): 283 - 291.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. C. Detterbeck, J. F. Vansteenkiste, D. E. Morris, C. A. Dooms, A. H. Khandani, and M. A. Socinski
Seeking a Home for a PET, Part 3: Emerging Applications of Positron Emission Tomography Imaging in the Management of Patients With Lung Cancer
Chest, November 1, 2004; 126(5): 1656 - 1666.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. Brenner, C. Vernon, M. Muzi, D. A. Mankoff, J. M. Link, E. U. Conrad, and J. F. Eary
Comparison of Different Quantitative Approaches to 18F-Fluoride PET Scans
J. Nucl. Med., September 1, 2004; 45(9): 1493 - 1500.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. Boellaard, N. C. Krak, O. S. Hoekstra, and A. A. Lammertsma
Effects of Noise, Image Resolution, and ROI Definition on the Accuracy of Standard Uptake Values: A Simulation Study
J. Nucl. Med., September 1, 2004; 45(9): 1519 - 1527.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. K. Sundaram, N. M.T. Freedman, J. A. Carrasquillo, J. M. Carson, M. Whatley, S. K. Libutti, D. Sellers, and S. L. Bacharach
Simplified Kinetic Analysis of Tumor 18F-FDG Uptake: A Dynamic Approach
J. Nucl. Med., August 1, 2004; 45(8): 1328 - 1333.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. A. Wieder, B. L.D.M. Brucher, F. Zimmermann, K. Becker, F. Lordick, A. Beer, M. Schwaiger, U. Fink, J. R. Siewert, H. J. Stein, et al.
Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment
J. Clin. Oncol., March 1, 2004; 22(5): 900 - 908.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. Boucher, S. Rodrigue, R. Lecomte, and F. Benard
Respiratory Gating for 3-Dimensional PET of the Thorax: Feasibility and Initial Results
J. Nucl. Med., February 1, 2004; 45(2): 214 - 219.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Ott, U. Fink, K. Becker, A. Stahl, H.-J. Dittler, R. Busch, H. Stein, F. Lordick, T. Link, M. Schwaiger, et al.
Prediction of Response to Preoperative Chemotherapy in Gastric Carcinoma by Metabolic Imaging: Results of a Prospective Trial
J. Clin. Oncol., December 15, 2003; 21(24): 4604 - 4610.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. A. Weber, V. Petersen, B. Schmidt, L. Tyndale-Hines, T. Link, C. Peschel, and M. Schwaiger
Positron Emission Tomography in Non-Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use
J. Clin. Oncol., July 15, 2003; 21(14): 2651 - 2657.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
E. Dizendorf, T. F. Hany, A. Buck, G. K. von Schulthess, and C. Burger
Cause and Magnitude of the Error Induced by Oral CT Contrast Agent in CT-Based Attenuation Correction of PET Emission Studies
J. Nucl. Med., May 1, 2003; 44(5): 732 - 738.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
M Schwaiger
Functional imaging for assessment of therapy
Br. J. Radiol., November 1, 2002; 75(90009): S67 - 73.
[Full Text] [PDF]

Home page
 JCOHome page
W. A. Weber, K. Ott, K. Becker, H.-J. Dittler, H. Helmberger, N. E. Avril, G. Meisetschlager, R. Busch, J.-R. Siewert, M. Schwaiger, et al.
Prediction of Response to Preoperative Chemotherapy in Adenocarcinomas of the Esophagogastric Junction by Metabolic Imaging
J. Clin. Oncol., June 15, 2001; 19(12): 3058 - 3065.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. A. Thie, K. F. Hubner, and G. T. Smith
The Diagnostic Utility of the Lognormal Behavior of PET Standardized Uptake Values in Tumors
J. Nucl. Med., October 1, 2000; 41(10): 1664 - 1672.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1999 by the Society of Nuclear Medicine.